Evaluation of multiple immunocompetent syngeneic tumor-bearing mouse models demonstrated that the baseline levels of CCR2-expressing intratumoral mMDSCs were positively associated with antitumor response to mTAK-500 (R2 = 0.87; P = 0.006; Supplementary Fig. S15). This evidence concerns the gene CCR2 and neoplasm.